<DOC>
	<DOCNO>NCT00495508</DOCNO>
	<brief_summary>A ) treatment uncomplicated malaria second third trimester pregnancy oral Quinine hydrochloride . The PCR-corrected adequate clinical parasitological response ( ACPR ) day 42 consider primary efficacy criterion . Newborns follow growth development indicator .</brief_summary>
	<brief_title>Quinine vs. Artemether/Lumefantrine Uncomplicated Malaria During Pregnancy</brief_title>
	<detailed_description>Study Title : Efficacy Safety Quinine v Artemether/Lumefantrine uncomplicated malaria pregnancy , Mbarara , Uganda ( 2006/2007 ) . Regulatory Status : Investigational - Phase IV Investigational Product route : - Quinine hydrochloride , oral route . - Coartem® ( Novartis Pharma AG , Basel , Switzerland ) , oral route . Lead Investigator Study Centre Primary objective - To establish , pregnant woman uncomplicated Plasmodium falciparum malaria , PCR-adjusted efficacy Artemether/Lumefantrine inferior oral Quinine . Secondary objectives - To define pharmacokinetics combination artemether-lumefantrine ( AL ) treatment uncomplicated P. falciparum infection last two trimester pregnancy . - To collect baseline data maternal , obstetric infant outcome . - To estimate incidence malaria infection , microscopic sub-microscopic ( PCR ) pregnancy . - woman attend Mbarara National Referral Hospital ( MNRH ) ante-natal clinic ( ANC ) . - Women positive blood smear follow-up invited participate non-inferiority , open , randomised , non- inferiority trial compare efficacy tolerance Coartem® ( Artemether-Lumefantrine ) treatment uncomplicated malaria second third trimester pregnancy oral Quinine hydrochloride . PCR-corrected adequate clinical parasitological response ( ACPR ) day 42 consider primary efficacy criterion . - Women uncomplicated malaria efficacy study , follow obtain efficacy endpoint 42 day OR delivery , whichever timepoint last . - Newborns follow monthly age 1 year . Inclusion Criteria ( Efficacy Study ) : - Pregnant woman - Malaria infection , detect microscopy , P. falciparum ( mixed mono-infection ) - Age gestation : 13 week beyond - Efficacy study sign informed consent form Exclusion Criteria ( Efficacy Study ) : - P. falciparum parasitaemia 250,000 parasites/μl - Severe anaemia - Signs symptom severe/complicated malaria require parenteral treatment ( WHO 2000 ) - Known allergy artemisinin derivative , lumefantrine quinine ; - Previous participation efficacy study - Inability attend efficacy study follow-up schedule . Study drug Administration - Group 1 ( Active Control ) : Quinine hydrochloride ( 10 mg/Kg/8h 7 day ) administer orally . - Group 2 ( Test ) : Coartem® , fix Artemether-Lumefantrine ( 20/120 mg ) GMP manufacture Novartis Pharma AG ( Basel , Switzerland ) , 4 tablet twice day 3 day 200 ml milk tea dose . Endpoints - Primary efficacy endpoint : PCR-corrected adequate clinical parasitological response ( ACPR ) Day 42 . - Secondary efficacy endpoint : - PCR-corrected ( ACPR ) delivery - Pharmacokinetic parameter - Symptom clearance Time - Proportion patient fever clear Day 1 , 2 3 - Safety endpoint : - Incidence adverse event - Pregnancy outcome - Infant development first year life</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Quinine</mesh_term>
	<criteria>Cohort Study : Weeks pregnancy 13 22 week Resident Mbarara Municipality ( radius 15km MNRH ) Cohort study sign informed consent form Efficacy Study : Pregnant woman Malaria infection , detect microscopy , P. falciparum ( mixed monoinfection ) Age gestation : 13 week beyond Efficacy study sign informed consent form Efficacy Study : P. falciparum parasitaemia 250,000 parasites/μl Severe anaemia Signs symptom severe/complicated malaria require parenteral treatment ( WHO 2000 ) Known allergy artemisinin derivative , lumefantrine quinine ; Previous participation efficacy study Inability attend efficacy study followup schedule .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Quinine</keyword>
	<keyword>Artemether</keyword>
	<keyword>Lumefantrine</keyword>
	<keyword>malaria</keyword>
	<keyword>Uganda</keyword>
	<keyword>Artemisinin- base combination therapy</keyword>
	<keyword>pregnancy</keyword>
	<keyword>Malaria In Pregnancy</keyword>
</DOC>